A MULTICENTER, RANDOMIZED, PROSPECTIVE DOUBLE-BLIND, CROSS OVER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 0.04 MMOL GD/KG BODY WEIGHT OF GADOQUATRANE FOR MRI IN ADULTS WITH KNOWN OR SUSPECTED PATHOLOGY OF THE CENTRAL NERVOUS SYSTEM (CNS), COMPARED TO 0.1 MMOL GD/KG APPROVED MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS (GBCAS)

Registry ID

21181

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BAYER INC

Start date

2024-02-23

Completion date

2024-12-17

Last update

2023-06-27

Conditions

• MRI IMAGING

Related clinical trials

• THE CANADIAN LUNG OUTCOMES IN USERS OF VAPING DEVICES (CLOUD) STUDY
• DEVELOPMENT OF HARDWARE AND SOFTWARE FOR PULMONARY MAGNETIC RESONANCE IMAGING USING INHALED TRACER GASES
• CANADIAN LONGITUDINAL STUDY OF LUNG STRUCTURE AND FUNCTION IN CANNABIS SMOKERS (CANUCK)
• A MECHANISTIC PILOT OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF BENRALIZUMAB ON AIRWAY FUNCTION AND INFLAMMATION IN PATIENTS WITH SEVERE, POORLY-CONTROLLED EOSINOPHILIC ASTHMA USING INHALED HYPERPOLARIZED 129XE MRI (AERFLO)
• NON-ISOTOPE BASED IMAGING MODALITIES VS 99MTC SPECT MYOCARDIAL PERFUSION IMAGING (MPI) TO DETECT MYOCARDIAL ISCHEMIA IN PATIENTS AT HIGH RISK FOR ISCHEMIC CARDIOVASCULAR EVENTS
• STRUCTURE AND FUNCTION MRI OF ASTHMA

View on source registry